Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876727 | 0.95 | HCAR2 (0.43) | HCAR2NPC1RAB9ARIPK1MAPT | |
| SCHEMBL6615884 | 0.91 | HCAR2 (0.41) | HCAR2NPC1RAB9ARIPK1MAPT | |
| SCHEMBL5876431 | 0.83 | HCAR2 (0.40) | HCAR2NPC1RAB9A | |
| SCHEMBL5876427 | 0.83 | HCAR2 (0.40) | HCAR2NPC1RAB9A | |
| SCHEMBL5876509 | 0.82 | NPC1 (0.53) | HCAR2NPC1RAB9ARIPK1SMN1; SMN2 | |
| SCHEMBL5877607 | 0.81 | KDM4E (0.43) | HCAR2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5876366 | 0.81 | HCAR2 (0.42) | HCAR2NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5876815 | 0.81 | HCAR2 (0.41) | HCAR2NPC1RAB9ARIPK1SMN1; SMN2 | |
| SCHEMBL5877819 | 0.80 | HCAR2 (0.36) | HCAR2NPC1RAB9A | |
| SCHEMBL5877821 | 0.80 | HCAR2 (0.36) | HCAR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
| EP-1414805-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | Aventis Pharma S.A. (FR) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011833-A1 | INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY | AVENTIS PHARMA S.A. (FR) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | HCAR2 398/4885NPC1 257/4885RAB9A 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.